Although a larger series of patient data are required to validate these results, these observations provide the evidence supporting the model wherein SOX2+/Sox2+ SHH-MB cells are more resistant to therapy-induced activation of p53-mediated tumor suppressive responses (e.g., cell-cycle arrest and neuronal differentiation) and responsible for tumor recurrence following de-escalating therapies. Here, SOX2 is linked to neoplasm.